Beijing Slian Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise integrating R&D, production and marketing, and is a national high-tech enterprise. Slian Pharmaceutical was initiated by Beijing Chuangying Technology Industry Group, and its business covers many fields such as reproductive health, maternal and child health, orthopedics, oncology, gynecology, pediatrics, and geriatrics. The company's headquarters is now located in Beijing Economic and Technological Development Zone, with business covering more than 700 cities in 30 provinces, cities and autonomous regions across the country.

The core variety of Slian Pharmaceutical "Slian Folic Acid Tablets" is a scientific research achievement achieved by the Chinese and American governments for 13 years, spending US$20 million and 250,000 medical observations. This achievement has been in more than 50 countries around the world. It has been adopted and has been published in famous domestic and foreign academic journals such as the Lancet, the New England Journal of Medicine, the Chinese Journal of Medicine, and the Chinese Journal of Epidemiology. "Slian Folic Acid Tablets" obtained a new drug certificate and production approval document issued by the Ministry of Health as early as 1997. Its quality standards have been designated as international standards by the World Health Organization and included in the Chinese Pharmacopoeia. "Slian Folic Acid Tablets" are promoted nationwide as a key project of the Ministry of Health's "100 Scientific and Technological Achievements in Ten Years" and have been rated as "National Key New Product" by the Ministry of Science and Technology, the Ministry of Commerce and other five ministries and commissions.

At present, small doses of folic acid have been widely used in various clinical disciplines and have been widely studied and highly recognized by experts from various disciplines at home and abroad. Many domestic and foreign studies have confirmed that taking small doses of folic acid every day can effectively reduce the level of homocysteine ​​in the body, becoming Intervention measures to effectively prevent and improve cardiovascular and cerebrovascular chronic diseases.

Slian Pharmaceutical has always adhered to the path of "intellectual innovation and developing enterprises with technology", increasing R&D investment year by year to enhance independent innovation capabilities, and the R&D results have been gradually transformed into independent intellectual property rights and core technologies of enterprises. It has obtained various patents. There are 100 items, including more than 30 invention patents, and a large number of new drugs such as the Class 1.2 new drug "Naoqing Zhiming Tablets" that prevents Alzheimer's disease have been successfully developed. The company has always focused on the fields of chronic diseases of maternal and child and elderly people, and now has many big health products such as Kingslian Duowei Tablets, calcium for pregnant women, DHA algae oil and calcium powder, shampoo and shower gel for pregnant women, toothpaste for pregnant women, etc.

Based on the long-term development strategy of the enterprise, Slian Pharmaceutical has invested in the construction of a production R&D base and production R&D base project in Zhongguancun National Independent Innovation Demonstration Zone Beijing Daxing Biopharma Industry Base. It covers an area of ​​38 mu, with a total investment of more than 300 million yuan, and was completed and put into production at the end of 2015. Among them, the production center successfully passed the GMP certification and ISO quality, environment, and occupational health system certification; the R&D center has R&D laboratories such as chemical preparations, chemical raw materials, traditional Chinese medicine, health products, food, daily chemicals, etc., and has R&D personnel Nearly 100 people, 50% of whom are master's and doctoral degrees, have the ability to undertake large-scale scientific research projects in the country, especially in the field of folic acid research, which is in the advanced position in China.

Slian Pharmaceutical is also investing in the construction of a raw material production and R&D base in the national development zone • National New Industrial Industry Demonstration Base • Cangzhou Lingang Economic and Technological Development Zone, Hebei Province in 2018. At present, protamine sulfate, prostene, fluorouracil, diphenhexol hydrochloride, ilyesamine and other raw materials have passed the GMP certification and are officially produced, meeting the market's demand for the country's shortage of drugs and won the favor of customers. And positive reviews.